Zobrazeno 1 - 10
of 138
pro vyhledávání: '"W. K. Evans"'
Autor:
P Canham, S Falder, Charalambos Yiannakaras, Easton R. White, Darshan H Brahmbhatt, Brendon Lalonde, Rob Gandy, Jian Wen Chan, Jean Rogers, H Tehrani, Brenda Roe, GP Rubin, Amanda Hey, Evripides Petrides, Andrew Smith, W K Evans, Ali El-Ghorr, Thalia Patsia, Julia Slark, Nathalie Assouad, Carol Sawka, Captain Philip Higton, Steven Laitner, W Horsley, Nicky Jb Trepte, Ruben van Zelm, A. Toby Prevost, R Thomson, Mary Avraamidou, Martin Knapp, Elmer J Catangui, Yee Ung
Publikováno v:
International Journal of Care Pathways. 15:100-106
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f19799cc6f5ddbecd8bb528ff8647fd6
https://doi.org/10.1258/jicp.2011.011m26
https://doi.org/10.1258/jicp.2011.011m26
Autor:
Rochelle Garner, S. Memon, E. Khoo, N. Mittmann, P. Manivong, W K Evans, C. Gauvreau, John R. Goffin, William M. Flanagan, N. Fitzgerald
Publikováno v:
Annals of Oncology. 29:viii568
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86736d7d106ae436b7f507fe40088820
https://doi.org/10.1093/annonc/mdy297.022
https://doi.org/10.1093/annonc/mdy297.022
Autor:
W. K. Evans, Eric J. Holowaty, Eric Gutierrez, Anthony Whitton, Alejandro R. Jadad, M. Fitch, Brian Golden, Esther Green, D. Soman
Publikováno v:
Clinical Oncology. 21:218-225
Aims To determine the utility of web-based radiation wait time information for patients and health care providers in decision-making. To revise the information using a simulated laboratory environment and to re-evaluate the new web-based information.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5373620b1c27d6a3d5122abeb4268b8b
https://doi.org/10.1016/j.clon.2008.12.003
https://doi.org/10.1016/j.clon.2008.12.003
Autor:
D. Logan, B P Will, Jean-Marie Berthelot, Michael Wolfson, William M. Flanagan, W K Evans, K M Nobrega
Publikováno v:
British Journal of Cancer
The Breast Cancer Prevention Trial (BCPT-P-1) demonstrated that tamoxifen could reduce the risk of invasive breast cancer in high-risk women by 49%, but that it could also increase the risk of endometrial cancer, vascular events and cataracts. This p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13c3cf2703b631010d279f45fab60064
https://doi.org/10.1054/bjoc.2001.2125
https://doi.org/10.1054/bjoc.2001.2125
Publikováno v:
Journal of Clinical Oncology. 19:3392-3396
PURPOSE: The previously described practice guidelines development cycle follows an iterative model in which recommendations are reached by a process that incorporates practitioners at all phases. A key feature is the separation of the evidence-based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cafda783fea79a157da857e3648bdf4a
https://doi.org/10.1200/jco.2001.19.14.3392
https://doi.org/10.1200/jco.2001.19.14.3392
Publikováno v:
European Journal of Cancer. 36:724-735
A comprehensive understanding of the cost components of common illnesses is a necessary first step towards ensuring optimal use of scarce healthcare resources. Since breast cancer is the commonest malignancy affecting Canadian women, we estimated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::010bc1c277a9bdfdff45e85abd0be227
https://doi.org/10.1016/s0959-8049(99)00340-8
https://doi.org/10.1016/s0959-8049(99)00340-8
Autor:
Annette M. O'Connor, Melissa C. Brouwers, Margaret B. Harrison, D. Logan, Ian D. Graham, Laura McAuley, Valerie A. Palda, W K Evans
Publikováno v:
Scopus-Elsevier
Purpose: To determine (1) Canadian oncologists’ attitudes toward practice guidelines, (2) oncologists’ self-reported use of practice guidelines and, (3) physicians’ characteristics and attitudes associated with self-reported use of practice gui
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1206fce0dc44296f54db4ead42cd8dd
https://doi.org/10.1159/000012184
https://doi.org/10.1159/000012184
Publikováno v:
British Journal of Cancer
The aim of this study was to assess the cost-effectiveness of combination chemotherapy with paclitaxel/cisplatin, compared with standard etoposide/cisplatin in patients with advanced non-small cell lung cancer (NSCLC). We obtained the primary surviva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::131f0992858e451adebfed3fbb3be9f0
https://doi.org/10.1038/sj.bjc.6690426
https://doi.org/10.1038/sj.bjc.6690426
Autor:
C.C. Earle, Stan Z. Gertler, Yvon Cormier, C. Mihalcioiu, P.D. Walde, David J. Stewart, W K Evans
Publikováno v:
Lung Cancer. 22:235-241
Purpose: To define the maximum tolerated dose and toxicity of combined cisplatin, etoposide, and gemcitabine in patients with small-cell lung cancer. Methods: We undertook a phase I study in patients with either extensive small-cell lung cancer with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43d9ee25b0385cd277839f4d9fb3d85f
https://doi.org/10.1016/s0169-5002(98)00085-3
https://doi.org/10.1016/s0169-5002(98)00085-3
Publikováno v:
Journal of Clinical Oncology. 15:3038-3048
PURPOSE To evaluate the cost-effectiveness (CE) of new combined modality strategies in patients with stage III non-small-cell lung cancer (NSCLC). METHODS Recent studies suggest that combined modality therapy confers a survival advantage for patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cca252dabdf5a8dd6fed2287fcd2619b
https://doi.org/10.1200/jco.1997.15.9.3038
https://doi.org/10.1200/jco.1997.15.9.3038